2021 Volume 47 Issue 1 Pages 54-59
Lonsurf® combination tablet (TAS102) is indicated for the treatment of patients with curatively unresectable, advanced, or recurrent colorectal cancer, and it is a pharmacological treatment option for later-line therapy. The dose intensity of TAS102 is affected by patients’ medication adherence. This study aimed to determine the relationship between the relative dose intensity (RDI) and treatment efficacy of TAS102. We analyzed the factors influencing progression free survival (PFS) with TAS102 treatment and found significant differences in PFS between those with an RDI ≥ 80％ and those with an RDI < 80％ and between those living with their family and those living alone. The median PFS was 49 days (95％ confidence interval [CI], 7 - 87) for those with an RDI < 80％ and 103 days (95％ CI, 63 - 133) for those with an RDI ≥ 80％, and the hazard ratio was 0.72 (95％ CI, 0.33 - 0.94; P = 0.03). The median PFS was 59 days (95％ CI, 21 - 116) for those living alone and 90 days (95％ CI, 58 - 124) for those living with their families, and the hazard ratio was 1.70 (95％ CI, 1.10 - 2.86; P = 0.04). RDI ≥ 80％ contributed to the prolongation of PFS. Our results also suggest that patients living alone need more drug administration guidance and support from healthcare providers.
